RT Book, Section
A1 Flynn, Patricia M.
A2 Rudolph, Colin D.
A2 Rudolph, Abraham M.
A2 Lister, George E.
A2 First, Lewis R.
A2 Gershon, Anne A.
SR Print(0)
ID 7024782
T1 Chapter 247. Antifungal Therapy
T2 Rudolph's Pediatrics, 22e
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-149723-7
LK accesspediatrics.mhmedical.com/content.aspx?aid=7024782
RD 2024/04/23
AB Antifungal  agents  are  available  in  systemic  and  topical  formulations,  and  some  are  available  in  both  forms.  Topical  antifungal  agents,  because  they  are  poorly  absorbed,  are  less  likely  to  cause  toxicity  and  should,  as  a  rule,  be  the  first  choice  for  treating  skin  and  mucous  membrane  infections.  However,  tinea  capitis  and  onychomycosis  (fungal  infection  of  the  nails)  are  best  treated  systemically  (see  Chapter  367).  Infections  that  are  severe,  are  disseminated,  or  involve  the  bloodstream  should  also  be  treated  with  systemic  therapy.  During  the  past  10  years,  many  potent  new  systemic  agents  have  become  available.  Organism-  and  disease-specific  antifungal  therapies  are  summarized  in  Table  247-1.